Systemic Therapies in the Management of Head and Neck Cancer

  • Andrew W. Maksymiuk
Part of the Head and Neck Cancer Clinics book series (HNCC)


The management of head and neck cancer (HNC) is evolving with the introduction of more effective treatment strategies. Current optimal treatment strategies incorporate principles of best practices and practice guidelines [1]. Predictive factors, such as age, stage, co-morbidity and human papillomavirus (HPV) status have been shown to relate to outcome, thus making for a more accurate estimation of prognosis. Factor analysis has the validity to assess the potential for cure as well as palliative end-points, such as time to treatment failure and estimated survival [2–5].


Positron Emission Tomography Chronic Obstructive Pulmonary Disease Epidermal Growth Factor Receptor Systemic Therapy Induction Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Pfister DG, Ang K, Brockstein B, et al. National Comprehensive Cancer Network. NCCN Practice Guidelines for Head and Neck Cancers. Oncology (Williston Park) 2000;14:163–94.Google Scholar
  2. 2.
    Argiris A, Karamouzls MV, Rabin D, et al. Head and neck cancer. Lancet 2008;371:1695–709.CrossRefPubMedGoogle Scholar
  3. 3.
    Expanding role of the medical oncologist in the management of head and neck cancer. CA: A Cancer Journal for Clinicians 2008;58:32–53.Google Scholar
  4. 4.
    Marur S, Forastiere AA. Head and neck cancer: Changing epidemiology, diagnosis, and treatment. Mayo Clin Proc 2008;83:489–501.CrossRefPubMedGoogle Scholar
  5. 5.
    Bhide SA, Nutting CM. Advances in chemotherapy for head and neck cancer. Oral Oncol 2010;46:436–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Pignon JP, le Maitre A, Maillard E, Bourhis J on behalf of the MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009;92:4(4–14).Google Scholar
  7. 7.
    Montoro JR, Hicz H, de Souza L, et al. Prognostic factors in squamous cell carcinoma of the oral cavity. Rev Bras Otorrinolaringol 2008;74:861–6.CrossRefGoogle Scholar
  8. 8.
    Alho O-P, Hannula K, Luokkala A, et al. Differential prognostic impact of co-morbidity in head and neck cancer. Head Neck 2007;29:913–18.CrossRefPubMedGoogle Scholar
  9. 9.
    Derksa W, de Leeuwb RJ, Jan Hordijka G. Elderly patients with head and neck cancer: The influence of comorbidity on choice of therapy, complication rate, and survival. Curr Opin Otolaryngol Head Neck Surg 2005;13:92–6.CrossRefGoogle Scholar
  10. 10.
    Al-Ibraheem A, Buck A, Krause BJ, et al. Clinical applications of FDG PET and PET/CT in head and neck cancer. J Oncol 2009;208725.Google Scholar
  11. 11.
    Kyzas PA, Evangelos E, Denaxa-Kyza D, et al. 18F-Fluorodeoxyglucose positron emission tomography to evaluate cervical node metastases in patients with head and neck squamous cell carcinoma: A meta-analysis. J Natl Cancer Inst 2008;100:712–20.CrossRefPubMedGoogle Scholar
  12. 12.
    Inokuchi H, Kodaira T, Tachibana H, et al. Clinical usefulness of [(18)] fluoro-2-deoxy-D-glucose uptake in 178 head-and-neck cancer patients with nodal metastasis treated with definitive chemoradiotherapy: Consideration of its prognostic value and ability to provide guidance for optimal selection of patients for planned neck dissection. Int J Radiation Oncology Biol Phys 2011;97:747–55.CrossRefGoogle Scholar
  13. 13.
    Gourin CG, Boyce BJ, Williams HT, et al. Revisiting the role of positron-emission tomography/computed tomography in determining the need for planned neck dissection following chemoradiation for advanced head and neck cancer. Laryngoscope 2009;119:2150–5.CrossRefPubMedGoogle Scholar
  14. 14.
    Egloff AM, Grandis JR. Improving response rates to EGFR-targeted therapies for head and neck squamous cell carcinoma: Candidate predictive biomarkers and combination treatment with Src inhibitors. J Oncol 2009;896407.Google Scholar
  15. 15.
    Ortholan C, Lusinchi A, Italiano AL, et al. Oral cavity squamous cell carcinoma in 260 patients aged 80 or more. Radiother Oncol 2009;93:516–23.CrossRefPubMedGoogle Scholar
  16. 16.
    Goon PKC, Stanley MA, Ebmeyer AJ, et al. HPV and head and neck cancer: A descriptive update. Head Neck Oncol 2009;1:36.PubMedCentralCrossRefPubMedGoogle Scholar
  17. 17.
    Pajares B, Trigo Perez JM, Toledo MD, et al. Human papillomavirus (HPV)-related head and neck squamous cell carcinoma (HNSCC) and outcome after treatment with epidermal growth factor receptor inhibitors (EGFR inhib) plus radiotherapy (RT) versus conventional chemotherapy (CT) plus RT. J Clin Oncol 2011;29 (suppl):367s, abstr 5528.Google Scholar
  18. 18.
    Fountzilas G, Tolis C, Kalogera-Fountzila A, et al. Paclitaxel, cisplatin, leucovorin, and continuous infusion fluorouracil for locally advanced squamous cell carcinoma of the head and neck. Medical Oncol 2005;22:269–79.CrossRefGoogle Scholar
  19. 19.
    Worden FP, Moon J, Samlowski W, et al. A phase II evaluation of 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck. Cancer 2006;107:319–27.CrossRefPubMedGoogle Scholar
  20. 20.
    Colevas AD, Norris CM, Tishler RB, et al. Phase II trial of docetaxel, cisplatin, fluorouracil, and leucovorin as induction for squamous cell carcinoma of the head and neck. J Clin Oncol 1999;17:3503–11.PubMedGoogle Scholar
  21. 21.
    Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007;357:1705–15.CrossRefPubMedGoogle Scholar
  22. 22.
    Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007;357:1695–704.CrossRefPubMedGoogle Scholar
  23. 23.
    Hitt R, Grau JJ, Lopez-Pousa A, et al. Final results of a randomized phase III trial comparing induction chemotherapy with cisplatin/5-FU or docetaxel/cisplatin/5-FU followed by chemo-radiotherapy (CRT) versus CRT alone as first-line treatment of unresectable locally advanced head and neck cancer (LAHNC). Proc Amer Soc Clin Oncol 2009;27 15S:303s abst 6009.Google Scholar
  24. 24.
    Hitt R, Lopez-Pousa A, Martinez-Trufero J, et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemo-radiotherapy in locally advanced head and neck cancer. J Clin Oncol 2005;23:8636–45.CrossRefPubMedGoogle Scholar
  25. 25.
    Fountzilas G, Bamias A, Kalogera-Fountzila A, et al. Induction chemotherapy with docetaxel and cisplatin followed by concomitant chemo-radiotheray in patients with inoperable non-nasopharyngeal carcinoma of the head and neck. Anticancer Res 2009;29:529–38.PubMedGoogle Scholar
  26. 26.
    Posner MR. Paradigm shift in the treatment of head and neck cancer: The role of neoadjuvant chemotherapy. The Oncologist 2005;10:11–19.CrossRefPubMedGoogle Scholar
  27. 27.
    Jacobs JR, Pajak TF, Kinzie J, et al. Induction chemotherapy in advanced head and neck cancer. Arch Otolaryngol Head Neck Surg 1987;113:193–7.CrossRefPubMedGoogle Scholar
  28. 28.
    Kish JA, Ensley JF, Jacobs JR, et al. Evaluation of high-dose cisplatin and 5-FU infusion as initial therapy in advanced head and neck cancer. Am J Clin Oncol 1988;11:553–7.CrossRefPubMedGoogle Scholar
  29. 29.
    Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 1991;324:1685–90.CrossRefGoogle Scholar
  30. 30.
    Al-Sarraf M, Martz K, Herskovick A, et al. Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: An intergroup study. J Clin Oncol 1997;1:277–84.Google Scholar
  31. 31.
    Schrijvers D, Vermorken JB. Taxanes in the treatment of head and neck cancer. Curr Opin Oncol 2005;17:218–24.CrossRefPubMedGoogle Scholar
  32. 32.
    Go RS, Adjei AA. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 1999;17:409–22.PubMedGoogle Scholar
  33. 33.
    Monk BJ, Burger RA, Parker R, et al. Development of an in vitro chemo-radiation response assay for cervical carcinoma. Gynecol Oncol 2002;87:193–9.CrossRefPubMedGoogle Scholar
  34. 34.
    Havemann D, Wolf M, Gorg C, et al. Preclinical and clinical experience with cisplatin and carboplatin and simultaneous radiation in non-small cell lung cancer. Ann Oncol 1992;3 [suppl3]:S33–S37.CrossRefGoogle Scholar
  35. 35.
    De Gramont A, Bosset J-F, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bi-monthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study. J Clin Oncol 1997;15:808–15.PubMedGoogle Scholar
  36. 36.
    Budd GT, Flemming TR, Bukowski RM, et al. 5-fluorouracil and folinic acid in the treatment of metastatic colorectal cancer: A randomized comparison. A Southwest Oncology Group study. J Clin Oncol 1987;5:272–7.PubMedGoogle Scholar
  37. 37.
    Poplin EA, Benedetti JK, Estes NC, et al. Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamasole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer. J Clin Oncol 2005;23:1918–25.CrossRefGoogle Scholar
  38. 38.
    Grogan L, Sotos GA, Allegra CJ. Leucovorin modulation of fluororouracil. Oncology (Williston Park) 1993;7:63–72.Google Scholar
  39. 39.
    Meta-Analysis Group in Cancer. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: An updated meta-analysis. J Clin Oncol 2004;22:3766–75.CrossRefGoogle Scholar
  40. 40.
    de Carvalho Fabricio V, Amado F, Del Giglio A. Low-cost outpatient chemotherapy regimen of cisplatin, 5-fluorouracil and leucovorin for advanced head and neck and esophageal carcinomas. Sao Paulo Med J 2008;126:63–6.CrossRefGoogle Scholar
  41. 41.
    Lefebvre JL, Rolland M Tessellaar M, et al. Phase 3 randomized trial on larynx preservation comparing sequential vs. alternating chemotherapy and radiotherapy. JNCI 2009;101:142–52.PubMedCentralCrossRefPubMedGoogle Scholar
  42. 42.
    Leichman CG, Flemming TR, Muggia FM, et al. Phase II study of fluorouracil and its modulation in advanced colorectal cancer. A Southwest Oncology Group study. J Clin Oncol 1995;13:1303–11.PubMedGoogle Scholar
  43. 43.
    Volkes E, Stenson K, Rosen FR, et al. Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemotherapy: Curative and organ-preserving therapy for advanced head and neck cancer. J Clin Oncol 2003;21:320–6.CrossRefGoogle Scholar
  44. 44.
    Ferrari D, Fiore J, Codeca C, et al. A phase II study of carboplatin and paclitaxel for recurrent or metastatic head and neck cancer. Anti-Cancer Drugs 2009;20:185–90.CrossRefPubMedGoogle Scholar
  45. 45.
    Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous cell carcinoma of the head and neck: A Southwest Oncology Group Study. J Clin Oncol 1992;10:1245–51.PubMedGoogle Scholar
  46. 46.
    Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567–78.CrossRefPubMedGoogle Scholar
  47. 47.
    Caudell JJ, Sawrie SM, Spencer SA, et al. Locoregionally advanced head and neck cancer treated with primary radiotherapy: A comparison of the addition of cetuximab or chemotherapy and the impact of protocol treatment. Int J Radiation Oncol Biol Phys 2008;713:676–81.CrossRefGoogle Scholar
  48. 48.
    Birnbaum A, Dipetrillo T, Rathore R, et al. Cetuximab, paclitaxel, carboplatin, and radiation for head and neck cancer. Am J Clin Oncol 2010;33:144–7.PubMedGoogle Scholar
  49. 49.
    Koukourakis MI, Tsoutsou PG, Karpouzis A, et al. Radiochemotherapy with cetuximab, cisplatin, and amifostine for locally advanced head and neck cancer: A feasibility study. Int J Radiation Oncology Biol Phys 2010;77:9–15.CrossRefGoogle Scholar
  50. 50.
    Liu L, Cao Y, Tan A, et al. Cetuximab-based therapy versus non-cetuximab therapy for advanced cancer: A meta-analysis of 17 randomized controlled trials. Cancer Chemother Pharmacol 2010;65:849–61.CrossRefPubMedGoogle Scholar
  51. 51.
    Kies MS, Holsinger FC, Lee JJ, et al. Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: Results from a phase II prospective trial. J Clin Oncol 2009;28:8–14.PubMedCentralCrossRefPubMedGoogle Scholar
  52. 52.
    Buiret G, Combe C, Favrel V, et al. A retrospective, multicenter study of the tolerance of induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil followed by radiotherapy with concomitant cetuximab in 46 cases of squamous cell carcinoma of the head and neck. Int J Radiation Oncol Biol Phys 2010;77:430–7.CrossRefGoogle Scholar
  53. 53.
    Bagust A, Greenhalgh J, Borland A, et al. Cetuximab for recurrent and/or metastatic squamous cell carcinoma of the head and neck: A NICE single technology appraisal. Pharmacoeconomics 2010;28:439–48.CrossRefPubMedGoogle Scholar
  54. 54.
    Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359:1116–27.CrossRefPubMedGoogle Scholar
  55. 55.
    Griffin S, Walker S, Sculpher M, et al. Cetuximab plus radiotherapy for the treatment of locally advanced squamous cell carcinoma of the head and neck. Health Technol Assess 2009;13:S49–S54.Google Scholar
  56. 56.
    Debucquoy A, Machiels J-P, McBride WH, et al. Integration of epidermal growth factor receptor inhibitors with preoperative chemoradiation. Clin Cancer Res 2010;16:2709–14.CrossRefPubMedGoogle Scholar
  57. 57.
    Cohen EEW, Rosen F, Stadler WM, et al. Phase II trial of ZD1039 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003;21:1980–7.CrossRefPubMedGoogle Scholar
  58. 58.
    Cohen EEW, Kane MA, List MA, et al. Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res 2005;11:8419–24.Google Scholar
  59. 59.
    Kirby AM, A’Hern RP, D’Ambrosio C, et al. Gefitinib (ZD1839) as palliative treatment in recurrent or metastatic head and neck cancer. B J Cancer 2006;94:631–6.Google Scholar
  60. 60.
    Cohen EEW, Davis DW, Karrison TG, et al. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: A phase I/II study. Lancet 2009;10:247–57.PubMedCentralCrossRefPubMedGoogle Scholar
  61. 61.
    Homma A, Shirato H, Furuta Y, et al. Randomized phase II trial of concomitant chemoradiotherapy using weekly carboplatin or daily low-dose cisplatin for squamous cell carcinoma of the head and neck. Cancer J 2004;10:326–32.CrossRefPubMedGoogle Scholar
  62. 62.
    Jeremic B, Shibamoto Y, Stanisavljevic B, et al. Radiation therapy alone or with concurrent low-dose daily either cisplatin or carboplatin in locally advanced unresectable squamous cell carcinoma of the head and neck: A prospective randomized trial. Radiother Oncol 1997;43:29–37.CrossRefPubMedGoogle Scholar
  63. 63.
    Beckmann GK, Hoppe F, Pfreundner L, et al. Hyperfractionated accelerated radiotherapy in combination with weekly cisplatin for locally advanced head and neck cancer. Head Neck 2005;27:36–43.CrossRefPubMedGoogle Scholar
  64. 64.
    Waltonen JD, Ozer E, Hall NC, et al. Metastatic carcinoma of the neck of unknown primary origin. Evolution and efficacy of the modern workup. Arch Otolaryngol Head Neck Surg 2009;135:1024–9.CrossRefPubMedGoogle Scholar
  65. 65.
    Lenzi R, Hess KR, Aburzzese MC, et al. Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown origin: Favorable subsets of patients with unknown-primary carcinoma? J Clin Oncol 1997;15:2056–66.PubMedGoogle Scholar
  66. 66.
    Staub E, Buhr HJ, Grone J. Predicting the site of origin of tumours by a gene expression signature derived from normal tissues. Oncogene 2010 [Epub].Google Scholar
  67. 67.
    Tao Y, Daly-Schveitzer N, Lusinchi A, et al. Advances in radiotherapy of head and neck cancers. Curr Opin Oncol 2010;22:194–9.CrossRefPubMedGoogle Scholar
  68. 68.
    Eisbruch A. IMRT reduces xerostomia and potentially improves QOL. Nature Reviews Clin Oncol 2009;6:567–8.CrossRefGoogle Scholar
  69. 69.
    Milano MR, Vokes EE, Kao J, et al. Intensity-modulated radiation therapy in advanced head and neck patients treated with intensive chemoradiotherapy: Preliminary experience and future directions. Intern J Oncol 2009;28:1141–51.Google Scholar
  70. 70.
    Jensen SB, Pederson AML, Anderson E, et al. A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: Management strategies and economic impact. Support Care Cancer 2010;18:1061–79.CrossRefPubMedGoogle Scholar
  71. 71.
    Brizel DM, Wasserman TH, Henke M, et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 2000;18:3339–45.PubMedGoogle Scholar
  72. 72.
    Koukourakis MI, Abatzoglou I, Sirridis L, et al. Individualization of the subcutaneous amifostine dose during hypofractionated/accelerated radiotherapy. Anticancer Res 2006;26:2437–43.PubMedGoogle Scholar
  73. 73.
    Valeyrie-Allanore L, Poulalhon N, Fagot J-P, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis induced by amifostine during head and neck radiotherapy. Radiotherapy Oncol 2008;87:300–3.CrossRefGoogle Scholar
  74. 74.
    Dische S. Radiotherapy and anaemia: The clinical experience. Radiother Oncol 2001;20:35–40.CrossRefGoogle Scholar
  75. 75.
    Harrison LB, Chadha M, Hill RJ, et al. Impact of tumor hypoxia and anemia on radiation therapy outcomes. Oncologist 2002;7:592–608.CrossRefGoogle Scholar
  76. 76.
    Glaspy J, Bukowski R, Steinberg D, et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 1997;15:1218–34.PubMedGoogle Scholar
  77. 77.
    Witzig TE, Silberstein PT, Loprinzi CL, et al. Phase III randomized double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 2005;23:2606–17.CrossRefPubMedGoogle Scholar
  78. 78.
    Hoskin PJ, Robinson M, Slevin N, et al. Effect of epoetin alfa on survival and cancer treatment-related anemia and fatigue in patients receiving radical radiotherapy with curative intent for head and neck cancer. J Clin Oncol 2009;27:5751–6.CrossRefPubMedGoogle Scholar

Copyright information

© The Author(s) 2012

Authors and Affiliations

  1. 1.Medical Oncology, CancerCare Manitoba, Department of Internal MedicineUniversity of ManitobaWinnipegCanada

Personalised recommendations